Cannara Biotech reports Q3 EPS C$0.05 vs. C$0.02 last year

Reports Q3 revenue C$27.3M vs. C$19.5M last year. “Fiscal Q3 2025 represents another record-breaking quarter for Cannara, producing records for revenue, gross profit, gross margin, adjusted EBITDA, adjusted EBITDA margin, operating cash flow, and free cash flow, showcasing the successful execution of our long-term business strategy, as well as our industry leadership,” stated Zohar Krivorot, CEO. “In addition to our stellar operating results, we have achieved two very significant milestones within our business. First, for the upcoming launch of Quebec’s high-demand vape category, the acceptance of 5 Cannara SKUs, pending final procedural steps, representing 20% of all accepted in-store SKUs by the province. Second, the optimization of our cultivation procedures which has resulted in a 26% yield improvement across our facilities, allowing Cannara to achieve our Fiscal 2026 cultivation target a full year ahead of schedule.”